Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-12-25
2007-12-25
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009200, C424S130100, C424S164100, C424S168100, C424S190100, C435S069100, C435S069300, C530S300000, C530S350000, C536S023100, C536S023700
Reexamination Certificate
active
09688672
ABSTRACT:
The present invention relates to fusion proteins containing at least twoMycobacteriumspecies antigens. In particular, it relates to nucleic acids encoding fusion proteins that include two or more individualM. tuberculosisantigens, which increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.
REFERENCES:
patent: 6592877 (2003-07-01), Reed et al.
patent: WO98/16646 (1998-04-01), None
patent: WO99/51748 (1999-10-01), None
Alderson, et al. “Expression cloning of an immunodominant family ofMycobacterium tuberculosisantigens using human CD4+T cells,”J. Exp. Med.191(3):551-559 (Feb. 7, 2000).
Brandt, et al. “ESAT-6 subunit vaccination againstMycobacterium tuberculosis,” Infect. Immun.68(2):791-795 (Feb. 2000).
Coler, et al. “Molecular cloning and immunologic reactivity of a novel low molecular mass antigen forMycobacterium tuberculosis,” J. Immunol.161(5):2356-2364 (Sep. 1, 1998).
Hendrickson, et al. “Mass Spectrometric Identification of Mtb81, A Novel Serological Marker for Tuberculosis,”J. Clin. Microbiol38(6):2354-2361 (Jun. 2000).
Leao, et al. “Immunological and functional characterization of proteins of theMycobacterium tuberculosisantigen 85 complex using synthetic peptides,”J. Gen. Microbiol.139:1543-1549 (1993).
Lowrie, et al. “Progress towards a new tuberculosis vaccine,”BioDrugs10(3):201-213 (Sep. 1998).
Vordermeier, et al. “Synthetic delivery system for tuberculosis vaccines: immunological evaluation of theM. tuberculosis38 kDa protein entrapped in biodegradable PLG microparticles,”Vaccine13(16):1576-1582 (1995).
Zimmerman, et al. “Immunization with peptide heteroconjugates primes a T helper cell type 1-associated antibody (IgG2a) response that recognizes the native epitope on the 38-kDa protein ofMycobacterium tuberculosis,” Vaccine Res.5(2):103-118 (1996).
Database EMBL [Online ] accession No. Z78020, XP002224823.
Database EMBL [Online ] accession No. Z17372, XP002224825.
Database EMBL [Online ] accession No. U90239, XP002224826.
Cole et al., “Deciphering the biology ofMycobacterium tuberculosisfrom the complete genome sequence”,Nature393: 537-544 (1998).
Dillon Davin C.
Houghton Raymond L.
Lodes Michael J.
McNeill Patricia D.
Reed Steven
Corixa Corporation
Swartz Rodney P
LandOfFree
Fusion proteins of mycobacterium tuberculosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion proteins of mycobacterium tuberculosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion proteins of mycobacterium tuberculosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3895005